At the J.P. Morgan Healthcare Conference, Hippocratic AI announced an expansion into the life sciences sector through the acquisition of Grove AI. Grove AI’s technology is designed to support clinical trial operations, with a focus on improving participant engagement, recruitment, and operational efficiency in regulated research environments.
Alongside the acquisition, Hippocratic AI created a dedicated life sciences division, appointed a president to lead the business, and established a life sciences executive advisory council to guide strategy and implementation. This move extends the company’s safety-focused, multi-agent AI platform beyond patient-facing care delivery into biopharma and medtech workflows, signaling a broader application of its agentic AI capabilities within clinical research and development.